News

News

Johnson & Johnson Announces Opening of London Innovation Centre

Description

<p>Johnson &amp; Johnson today announced the opening of the Johnson &amp; Johnson Innovation centre in London, one of four regional hubs being established this year in the world’s leading innovation hotspots. A part of Johnson &amp; Johnson Innovation, the goal of the London innovation centre is to accelerate the best early stage science in the world and advance the development of new healthcare solutions.</p>

Front teaser image

Janssen, Johnson & Johnson Innovation, Announce Collaboration With Belgian Scientists To Pursue New Research in Neurodegenerative Diseases

Description

<p>Janssen Research &amp; Development, Division of Janssen Pharmaceutica NV, and Johnson &amp; Johnson Innovation today announced the launch of a collaborative initiative with scientists from three prominent Belgian academic institutions and research centers to drive discoveries to improve the prevention, diagnosis and treatment of neurodegenerative diseases. Janssen Research &amp; Development and Johnson &amp; Johnson Innovation are committing up to 5 million Euros for this project over a five-year period.</p>

Front teaser image

Johnson & Johnson Innovation Announces Opening of the California Innovation Center

Description

<p>Johnson &amp; Johnson Innovation today announced the opening of the Johnson &amp; Johnson California Innovation Center, one of four regional hubs being established in the world’s leading life science innovation hotspots. A part of Johnson &amp; Johnson Innovation, the goal of the California Innovation Center is to advance healthcare by catalyzing collaborations in science and technology between regional innovators and the Johnson &amp; Johnson Family of Companies across a diverse spectrum of early stage innovation.</p>

Front teaser image

Johnson & Johnson Announces Opening of Boston Innovation Center

Description

<p>Johnson &amp; Johnson today announced the opening of the Johnson &amp; Johnson Innovation center in Boston, the third of four regional hubs being established in the world's leading life science hotspots. A part of Johnson &amp; Johnson Innovation, the goal of the Boston Innovation Center is to advance healthcare by catalyzing collaborations in science and technology between regional innovators and the Johnson &amp; Johnson Family of Companies across a diverse spectrum of early-stage opportunities.</p>

Front teaser image

Johnson & Johnson Innovation Announces Finalists of Cognition Challenge

Description

<p>Johnson &amp; Johnson Innovation today announced the finalists of the Cognition Challenge. The Cognition Challenge, a program supported by the Consulate General of Canada in partnership with Johnson &amp; Johnson Innovation and its affiliate Janssen Research &amp; Development, LLC, is a crowd-sourcing inspired challenge that invited Canadian researchers and entrepreneurs to submit their solutions to address problems of learning and memory related to Alzheimer’s disease and cognitive disorders.</p>

Front teaser image

Johnson & Johnson Innovation Establishes Network of Partnering Offices in UK Life Sciences Clusters

Description

<p>Johnson &amp; Johnson Innovation, London, today announces the formation of a network of partnering offices across UK life science clusters. The offices function as extensions of its London Innovation Centre to work with academics and entrepreneurs throughout the UK to identify early stage innovation and support the translation of research into new products for patients.</p>

Johnson & Johnson Innovation Expands Global Incubator Presence to Israel and Announces Multiple, Diverse, Early-Stage Collaborations with Academia and Biotech

Description

<p>Johnson &amp; Johnson Innovation today announced that it is expanding its global incubator presence through a novel collaboration with the Office of the Chief Scientist in Israel and other industry partners to establish a new biotechnology incubator near Israel’s Weizmann Science Park. This is the latest in a series of recently announced collaborations to fuel entrepreneurship in the world’s scientific hotspots. In addition, Johnson &amp; Johnson Innovation announced several new collaborations with academia and biotech that focus on multiple disease areas and consumer healthcare challenges.</p>

Front teaser image

Johnson & Johnson Innovation Announces Collaborations with Two Canadian Early-Stage Drug Technology Development Centers

Description

<p>Johnson &amp; Johnson Innovation and its affiliate Janssen Inc. in Canada today announced new collaborations with two Canadian early-stage drug technology development centers, Montreal-based NEOMED and Toronto-based MaRS Innovation, to identify and advance promising bio/pharmaceutical technologies that have the potential to impact human health.</p>

Front teaser image

Johnson & Johnson Announces Plans to Establish Innovation Centers

Description

<p>Johnson &amp; Johnson today announced plans to establish four regional innovation centers in major life sciences communities in the world as part of a novel approach to accelerate early innovation and enhance opportunities for collaboration and investment across its global healthcare businesses.</p>

Front teaser image

Johnson & Johnson Innovation Celebrates Life Science Innovation

Description

<p>Johnson &amp; Johnson Innovation today announced several new collaborations in the European region to coincide with a ‘Celebration of Life Science Innovation’ event, hosted by its London Innovation Centre. The event brings together UK life science leaders and scientists from the Johnson &amp; Johnson Family of Companies to celebrate promising advances and discuss novel collaboration models to deliver better healthcare solutions for patients around the world.&nbsp;</p>

Johnson & Johnson Innovation Announces Immuno-Oncology Lung Cancer Collaboration with the Dana-Farber Cancer Institute’s Belfer Institute for Applied Cancer Science

Description

<p>Johnson &amp; Johnson Innovation, Boston and Janssen Biotech, Inc. today announced a three-year immuno-oncology lung cancer collaboration with the Dana-Farber Cancer Institute. Through the collaboration, Janssen scientists will work with the research team at Dana-Farber’s Belfer Institute for Applied Cancer Science to determine the clinical setting for certain immuno-oncology agents in Janssen’s lung cancer discovery pipeline.</p>

Front teaser image

Johnson & Johnson Innovation Announces New J-Labs Incubator at Texas Medical Center

Description

<p>Johnson &amp; Johnson Innovation, LLC., today announced plans to expand J-Labs (formerly called Janssen Labs) to include a new incubator located within Texas Medical Center’s new Innovation Institute. This facility is located at 2450 Holcombe Boulevard, Houston, TX. The 30,000-square foot J-Labs facility will accommodate up to 50 life science startups.</p>

Front teaser image

Johnson & Johnson Innovation Launches Asia Pacific Innovation Center and Announces New Alliances

Description

<p>Johnson &amp; Johnson Innovation today announced the opening of the Asia Pacific Innovation Center, located in Shanghai with satellites in Singapore, Australia and Japan. The Asia Pacific Innovation Center extends the network of Johnson &amp; Johnson Innovation Centers in life sciences hotspots around the globe. With local science and technology experts and deal-making capabilities, the Center will identify and develop promising early-stage opportunities across the Company’s three areas of focus: Pharmaceuticals, Medical Devices and Diagnostics and Consumer healthcare products.&nbsp;</p>

Front teaser image

Janssen and Johnson & Johnson Innovation Announce License Agreement with Vedanta Biosciences for Microbiome Pharmaceutical Candidate for Inflammatory Bowel Disease

Description

<p>Janssen and Johnson &amp; Johnson Innovation Announce License Agreement with Vedanta Biosciences for Microbiome Pharmaceutical Candidate for Inflammatory Bowel Disease Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson, today announced a license agreement with Vedanta Biosciences for the company’s lead microbiome pharmaceutical candidate (VE202), which in published preclinical studies has demonstrated efficacy in models of autoimmune disease.&nbsp; Under terms of the agreement, facilitated by the Johnson &amp; Johnson Innovation Center in Boston, Janssen will develop and seek to commercialize the pharmaceutical candidate in inflammatory bowel disease.</p>

Front teaser image